498 related articles for article (PubMed ID: 23287851)
21. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
Urban D; Bar J; Solomon B; Ball D
J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
[TBL] [Abstract][Full Text] [Related]
22. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
[TBL] [Abstract][Full Text] [Related]
23. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
[TBL] [Abstract][Full Text] [Related]
24. Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.
Robinson BM; Kennedy C; McLean J; McCaughan BC
J Thorac Oncol; 2011 Oct; 6(10):1691-6. PubMed ID: 21869717
[TBL] [Abstract][Full Text] [Related]
25. [Expression and diagnostic application of C4.4A protein in squamous cell carcinoma and adenocarcinoma].
Wang W; Ding YQ; Li ZG; Han HX; Yang L
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):277-80. PubMed ID: 16776998
[TBL] [Abstract][Full Text] [Related]
26. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
[TBL] [Abstract][Full Text] [Related]
27. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
28. Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC).
Hötzel J; Melling N; Müller J; Polonski A; Wolters-Eisfeld G; Izbicki JR; Karstens KF; Tachezy M
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2285-2292. PubMed ID: 31372722
[TBL] [Abstract][Full Text] [Related]
29. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.
Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Bando T; Date H
Ann Surg Oncol; 2014 Aug; 21(8):2546-54. PubMed ID: 24633668
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
Gomez-Roca C; Raynaud CM; Penault-Llorca F; Mercier O; Commo F; Morat L; Sabatier L; Dartevelle P; Taranchon E; Besse B; Validire P; Italiano A; Soria JC
J Thorac Oncol; 2009 Oct; 4(10):1212-20. PubMed ID: 19687761
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
Mattsson JS; Bergman B; Grinberg M; Edlund K; Marincevic M; Jirström K; Pontén F; Hengstler JG; Rahnenführer J; Karlsson MG; Karlsson C; Helenius G; Botling J; Micke P; Gulyas M
Cancer Lett; 2015 Jan; 356(2 Pt B):837-45. PubMed ID: 25449785
[TBL] [Abstract][Full Text] [Related]
32. TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis.
Huang AL; Liu SG; Qi WJ; Zhao YF; Li YM; Lei B; Sheng WJ; Shen H
Asian Pac J Cancer Prev; 2014; 15(19):8143-7. PubMed ID: 25338997
[TBL] [Abstract][Full Text] [Related]
33. C4.4A expression is associated with a poor prognosis of esophageal squamous cell carcinoma.
Ohtsuka M; Yamamoto H; Masuzawa T; Takahashi H; Uemura M; Haraguchi N; Nishimura J; Hata T; Yamasaki M; Miyata H; Takemasa I; Mizushima T; Takiguchi S; Doki Y; Mori M
Ann Surg Oncol; 2013 Aug; 20(8):2699-705. PubMed ID: 23435632
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract][Full Text] [Related]
35. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
[TBL] [Abstract][Full Text] [Related]
36. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung.
Pelosi G; Fraggetta F; Pasini F; Maisonneuve P; Sonzogni A; Iannucci A; Terzi A; Bresaola E; Valduga F; Lupo C; Viale G
Am J Surg Pathol; 2001 Mar; 25(3):363-72. PubMed ID: 11224607
[TBL] [Abstract][Full Text] [Related]
37. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Kamide Y; Ishizuka T; Kanai Y; Nakajima T; Mori M
Ann Surg Oncol; 2009 Dec; 16(12):3473-81. PubMed ID: 19777189
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage I adenocarcinoma and squamous cell carcinoma of the lung.
Kinoshita T; Ohtsuka T; Yotsukura M; Asakura K; Goto T; Kamiyama I; Otake S; Tajima A; Emoto K; Hayashi Y; Kohno M
J Thorac Oncol; 2015 Apr; 10(4):619-28. PubMed ID: 25634009
[TBL] [Abstract][Full Text] [Related]
39. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
[TBL] [Abstract][Full Text] [Related]
40. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma.
Neri S; Ishii G; Taira T; Hishida T; Yoshida J; Nishimura M; Nagai K; Ochiai A
Ann Surg Oncol; 2012 Nov; 19(12):3953-62. PubMed ID: 22669451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
